Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adrenal suppression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Adrenal suppression. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-003241-15 Sponsor Protocol Number: SCH/12/043 Start Date*: 2012-10-09
    Sponsor Name:Sheffield Children's NHS Foundation Trust
    Full Title: NeSST2: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered Synacthen and salivary cortisol. The validated non-invasive SST will be used to e...
    Medical condition: In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal Synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establi...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064973 Allergic bronchospasm LLT
    15.0 10014698 - Endocrine disorders 10001367 Adrenal insufficiency PT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013355-29 Sponsor Protocol Number: SCH/09/018 Start Date*: 2010-07-02
    Sponsor Name:Sheffield Children's NHS Foundation Hospital
    Full Title: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered synacthen and salivary cortisol. The validated non-invasive SST will be used to establish...
    Medical condition: In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establi...
    Disease: Version SOC Term Classification Code Term Level
    9.0 10001367 Adrenal Insufficiency PT
    9.0 10006482 Bronchospasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000051-10 Sponsor Protocol Number: A091200 Start Date*: 2008-05-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: 11C metomidate PET scanning for Conn's syndrome
    Medical condition: Primary hyperaldosteronism - Conn's syndrome and bilateral adrenal hyperplasia. Imaging of adrenal lesions using 11C-metomidate PET. Pre-suppression with dexamethasone and/or fludrocortisone to opt...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005822-23 Sponsor Protocol Number: REK231814 Start Date*: 2012-10-16
    Sponsor Name:Haukeland University Hospital
    Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA
    Medical condition: Congenital adrenal hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002008-41 Sponsor Protocol Number: GR-MET-19 Start Date*: 2019-09-05
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome
    Medical condition: patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000748-32 Sponsor Protocol Number: SPI-62-CL-2002 Start Date*: 2023-08-29
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
    Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000161-40 Sponsor Protocol Number: AdrenalClock Start Date*: 2022-07-18
    Sponsor Name:Medical University of Vienna, Division of Endocrinology
    Full Title: Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion
    Medical condition: Autonomous cortisol secretion in patients with adrenal adenoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000462-33 Sponsor Protocol Number: 171-7151-202 Start Date*: 2023-04-19
    Sponsor Name:Intrepid Therapeutics, Inc.
    Full Title: An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects with Acn...
    Medical condition: Facial Acne Vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004956-12 Sponsor Protocol Number: CORT125134-456 Start Date*: 2021-02-24
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-...
    Medical condition: Hypercortisolism
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000866-40 Sponsor Protocol Number: 2012-000866-40 Start Date*: 2012-03-12
    Sponsor Name:ISTITUTO ORTOPEDICO RIZZOLI
    Full Title: Evaluation of the efficacy and suppression of the hypothalamic-pituitary-adrenal axis resulting in intrabursale single administration of cortisone in patients with calcific tendonitis of the rotato...
    Medical condition: calcific tendonitis of the rotator cuff
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003845-40 Sponsor Protocol Number: 122-0551-209 Start Date*: 2019-07-09
    Sponsor Name:Mayne Pharma LLC
    Full Title: An open label evaluation of the adrenal suppression potential and pharmacokinetic properties of twice daily halobetasol propionate foam, 0.05% in subjects 12 to less than 18 years of age with plaqu...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002406-43 Sponsor Protocol Number: V01-118A-401 Start Date*: 2020-07-31
    Sponsor Name:Bausch Health Americas, Inc.(affiliate of Bausch Health US , LLC, formerly known as Dow Pharmaceutical Sciences)
    Full Title: A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion i...
    Medical condition: Moderate to severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000616-15 Sponsor Protocol Number: CB-03-01/28 Start Date*: 2016-05-25
    Sponsor Name:Cassiopea S.P.A.
    Full Title: An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <...
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002209-23 Sponsor Protocol Number: V01-122A-401 Start Date*: 2020-07-22
    Sponsor Name:Bausch Health Americas, Inc.(affiliate of Bausch Health US ,formerly known as Dow Pharmaceutical Sciences)
    Full Title: A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion i...
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004983-23 Sponsor Protocol Number: 201900874 Start Date*: 2021-01-18
    Sponsor Name:University Medical Center Groningen
    Full Title: Bioequivalence study of prednisolone and dexamethasone: corticosteroids revisited
    Medical condition: This study does not investigate a medical condition and is performed in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002704-27 Sponsor Protocol Number: VBP15-004-A4 Start Date*: 2019-07-06
    Sponsor Name:ReveraGen BioPharma, Inc.
    Full Title: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne...
    Medical condition: Duchenne muscular dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) GR (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-000899-23 Sponsor Protocol Number: CORT125134-451 Start Date*: 2016-08-16
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001104-37 Sponsor Protocol Number: ME/2011/3709 Start Date*: 2014-10-06
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia
    Medical condition: Addison's disease and Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10011195 Cortisol LLT
    17.0 100000004848 10020518 Hydrocortisone LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-004495-36 Sponsor Protocol Number: M90-516 Start Date*: 2014-11-28
    Sponsor Name:Abbvie previously known as Abbott
    Full Title: Study of Lupron Depot in the Treatment of Central Precocious Puberty
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002133-37 Sponsor Protocol Number: COR-2012-01 Start Date*: 2014-11-17
    Sponsor Name:Cortendo AB
    Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:28:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA